SAN DIEGO, October 4, 2017 – ViaCyte, Inc., a privately-held regenerative medicine company, today announced upcoming company presentations at the Cell and Gene Meeting on the Mesa and the BIO Investor Forum. In addition, ViaCyte has been selected to participate in this year’s TEDxSanDiego Innovation Alley. ViaCyte is developing novel stem cell-derived islet replacement therapies for insulin-requiring diabetes. ViaCyte’s product candidates have the potential to provide a functional cure for patients with type 1 diabetes as well as an important therapy for patients with type 2 diabetes that depend on insulin to help control their disease.
“These events offer several venues and platforms to share the exciting progress ViaCyte is making in developing novel cell replacement therapies for diabetes,” said Paul Laikind, PhD, President and CEO of ViaCyte. “This year we were honored to join forces with a new research partner and investor, W.L. Gore & Associates, and garner continued support from long-time investors, which includes new funding from both JDRF and the California Institute for Regenerative Medicine. The funding will help support our current clinical trial evaluating the safety and efficacy of ViaCyte’s PEC-Direct product candidate, which is in development as a potential cure for patients with high-risk type 1 diabetes. Recognizing there is still a tremendous need for better diabetes treatments, ViaCyte remains dedicated to developing cell replacement technologies as a way to significantly improve patients’ lives.”
Details of the presentations are as follows:
Event: Cell and Gene Meeting on the Mesa & Partnering Forum
Speaker: Paul Laikind, Ph.D., President and CEO of ViaCyte
Date/Time: October 5, 9:45 am PT
Location: La Jolla, California
Event: TEDxSanDiego Innovation Alley 2017
Date/Time: October 14, 11:00 am – 3:00 pm PT
Location: San Diego, California
Event: BIO Investor Forum
Speaker: Dr. Laikind
Date/Time: October 17, 11:00 am PT
Location: San Francisco, California
For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells from stem cells, which are then implanted in a durable and retrievable cell delivery device. Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels. ViaCyte has two products in development. The PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients who have severe hypoglycemic episodes, extreme glycemic lability, and/or impaired awareness of hypoglycemia. The PEC-Encap™ (also known as VC-01) product candidate delivers pancreatic progenitor cells in an immunoprotective device and is currently being evaluated in a Phase 1/2 trial in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte is headquartered in San Diego, California. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.